Japan Cell and Gene Therapy Market Introduction and Overview
According to SPER Market Research, the Japan Cell and Gene Therapy Market is estimated to reach USD 9744.68 million by 2033 with a CAGR of 12.71%.
The report includes an in-depth analysis of the Japan Cell and Gene Therapy Market, including market size and trends, product mix, applications, and supplier analysis. Gene therapy is a new medical method that aims to address and potentially eliminate diseases by modifying genes within an individual's cells. This advanced approach involves the introduction, deletion, or modification of genetic information in a patient's cells, with the primary goal of correcting genetic defects that cause various diseases. Therapeutic deoxyribonucleic acid (DNA), a delivery vector that permits DNA transfer into cells, and advanced gene-editing tools, such as CRISPR, are required for gene therapy to function. It has a wide range of applications, including cancer treatment, viral infection management, cardiovascular disease (CVD), neurological disorders, autoimmune diseases, age-related illnesses, specific types of blindness, and genetic disorders such as hemophilia, cystic fibrosis, and sickle cell disease.
- Johnson & Johnson announced in April 2024 that the United States Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel), a CAR T-cell treatment that targets the B-cell maturation antigen (BCMA).
- Bristol Myers Squibb (BMS) and 2seventy Bio, Inc. announced in April 2024 that the United States Food and Drug Administration (FDA) had authorized ABECMA (idecabtagene vicleucel) for adult patients with relapsed or refractory multiple myeloma who had received two or more prior lines of therapy.
Market Opportunities and Challenges
Opportunities- The market for cell and gene therapy in Japan is quickly becoming one of the most vibrant and promising areas of the nation's healthcare system. The need for novel treatments that can provide long-term solutions is increased due to an aging population and an increase in the prevalence of chronic illnesses. Because of their potential to treat unmet medical needs, cell and gene therapy have attracted a lot of interest and investment in Japan. Using these state-of-the-art technologies, Japanese researchers and biopharmaceutical companies have been actively working on generating innovative medicines. Japan is a desirable market for both domestic and foreign companies since regulatory bodies there have also taken action to support the clinical development and commercialization of cell and gene treatments.
Challenges:
High Manufacturing prices - Cell and gene therapy manufacturing entails intricate and resource-intensive processes, which raises production prices. The broad use and accessibility of these treatments are hampered by their exorbitant costs.
Regulatory and Reimbursement Difficulties - Cell and gene therapies face a changing and sometimes complicated regulatory environment. The commercialization and accessibility of these treatments may be impacted by the time and resource commitment required to navigate reimbursement procedures and obtain regulatory clearances.
Market Competitive Landscape
There are many businesses operating in the fiercely competitive cell and gene therapy manufacturing market. Important market participants include: Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Therapy Type, By Indication, By Delivery Mode, By End User |
| Regions covered | Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region. |
| Companies Covered | Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT. |
By Therapy Type Insights:
It is anticipated that the cell therapy market would expand significantly over the course of the projected period. Cell therapy is a state-of-the-art therapeutic approach in which patients get living cells to cure a variety of illnesses. Both allogeneic and autologous cells are used in this therapeutic strategy. Because of its potential for individualized medicine, the cell therapy business is expanding significantly. To meet the growing need for innovative therapies for chronic illnesses, businesses are creating cell therapy products using a variety of cell lines, including stem cells.
COVID-19 Impact on Japan Cell and Gene Therapy Market
The COVID-19 pandemic has had a substantial influence on the cell and gene therapy manufacturing sector.
Accelerated Research and Development - The pandemic has spurred research and development of cell and gene treatments, which have the potential to treat COVID-19 and related problems.
Regulatory Adjustments - Regulatory bodies have facilitated faster development and production of COVID-19-related cell and gene therapies by offering flexibilities and accelerated approval pathways.
Key Target Audience:
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Healthcare Providers and Hospitals
- Regenerative Medicine Companies
- Contract Research and Manufacturing Organizations (CROs and CMOs)
- Government and Regulatory Bodies
- Investors and Venture Capitalists
- Patient Advocacy Groups
- Specialized Clinics
- Medical Device Manufacturers
Our in-depth analysis of the Japan Cell and Gene Therapy Market includes the following segments:
| By Therapy Type: | Cell TherapyStem CellNon-Stem CellGene Therapy |
| By Indication: | Cardiovascular DiseaseOncology DisorderGenetic DisorderInfectious DiseaseNeurological DisorderOthers |
| By Delivery Mode: | In-VivoEx-Vivo |
| By End User: | HospitalsCancer Care CentersPharmaceutical and Biotechnology CompaniesOthers |
Key Topics Covered in the Report:
- Japan Cell and Gene Therapy Market Size (FY’2024-FY’2033)
- Overview of Japan Cell and Gene Therapy Market
- Segmentation of Japan Cell and Gene Therapy Market by Therapy Type (Cell Therapy, Gene Therapy)
- Segmentation of Japan Cell and Gene Therapy Market by Indication (Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, and Others)
- Segmentation of Japan Cell and Gene Therapy Market by Delivery Mode (In-Vivo, Ex-Vivo)
- Segmentation of Japan Cell and Gene Therapy Market by End User (Hospitals, Cancer Care Centers, Pharmaceutical and Biotechnology Companies, and Others)
- Statistical Snap of Japan Cell and Gene Therapy Market
- Expansion Analysis of Japan Cell and Gene Therapy Market
- Problems and Obstacles in Japan Cell and Gene Therapy Market
- Competitive Landscape Japan Cell and Gene Therapy Market
- Impact of COVID-19 and Demonetization Japan Cell and Gene Therapy Market
- Details on Current Investment in Japan Cell and Gene Therapy Market
- Competitive Analysis of Japan Cell and Gene Therapy Market
- Prominent Players in the Japan Cell and Gene Therapy Market
- SWOT Analysis of Japan Cell and Gene Therapy Market
- Japan Cell and Gene Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan Cell and Gene Therapy Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Japan Cell and Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cell and Gene Therapy Market
7. Japan Cell and Gene Therapy Market, By Therapy Type (USD Million) 2020-2033
7.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2020-2026
7.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2027-2033
7.3. Cell Therapy
7.3.1. Stem Cell
7.3.2. Non-Stem Cell
7.4. Gene Therapy
8. Japan Cell and Gene Therapy Market, By Indication (USD Million) 2020-2033
8.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Cardiovascular Disease
8.4. Oncology Disorder
8.5. Genetic Disorder
8.6. Infectious Disease
8.7. Neurological Disorder
8.8. Others
9. Japan Cell and Gene Therapy Market, By Delivery Mode (USD Million) 2020-2033
9.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2020-2026
9.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2027-2033
9.3. In-Vivo
9.4. Ex-Vivo
10. Japan Cell and Gene Therapy Market, By End User (USD Million) 2020-2033
10.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2020-2026
10.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2027-2033
10.3. Hospitals
10.4. Cancer Care Centers
10.5. Pharmaceutical and Biotechnology Companies
10.6. Others
11. Japan Cell and Gene Therapy Market Forecast, 2020-2033 (USD Million)
11.1. Japan Cell and Gene Therapy Market Size and Market Share
12. Japan Cell and Gene Therapy Market, By Region, 2020-2033 (USD Million)
12.1. Japan Cell and Gene Therapy Market Size and Market Share By Region (2020-2026)
12.2. Japan Cell and Gene Therapy Market Size and Market Share By Region (2027-2033)
12.3. Kanto Region
12.4. Kansai/Kinki Region
12.5. Central/ Chubu Region
12.6. Kyushu-Okinawa Region
12.7. Tohoku Region
12.8. Chugoku Region
12.9. Hokkaido Region
12.10. Shikoku Region
13. Company Profile
13.1. Bristol-Myers Squibb Company
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. 2seventy bio, Inc
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Novartis AG
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Gilead Sciences Inc
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Spark Therapeutics, Inc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Nipro Corporation
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. JCR Pharmaceuticals Co., Ltd
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Aurion Biotech
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Johnson & Johnson Services, Inc
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Terumo BCT
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links